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Background: Thymoma is a rare malignancy of unknown etiology.
Methods: The author examined patterns in thymoma incidence in
the US general population using data from Surveillance, Epidemi-
ology, and End Results (SEER) cancer registries. Prior studies
concerning the risk of additional malignancies in thymoma patients
were reviewed.
Results: Based on cancer registry data, the overall incidence of thy-
moma in the US is 0.13 per 100,000 person-years. Thymoma is
exceedingly uncommon in children and young adults, rises in incidence
in middle age, and peaks in the seventh decade of life. Thymoma
incidence is especially high among Asians and Pacific Islanders in the
US. While several studies based at single treatment centers have
suggested that thymoma patients have a broadly increased risk for other
malignancies, follow up data from US cancer registries support a more
limited spectrum of cancer risk. In particular, thymoma patients have a
subsequently elevated risk for developing B-cell non-Hodgkin’s lym-
phoma. Based on limited data, thymoma patients may also have an
elevated risk for developing soft tissue sarcomas.
Discussion: Thymoma is a rare malignancy. The excess risk for
non-Hodgkin’s lymphoma is consistent with an effect of immune
disturbance arising from the thymoma or its treatment. While de-
scriptive epidemiologic data may yield clues to the etiology of
thymoma, large multi-center case-control studies will be required to
formally evaluate environmental and genetic risk factors.
Key Words: Thymoma, Epidemiology, Secondary malignancies,
Sarcomas, Cancer registries, Non-Hodgkin’s lymphoma.
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As the site of maturation for T cells, the thymus plays acentral role in adaptive immunity. Although primary tumors
of the thymus are rare, the most common histologic type is
thymoma, a neoplasm of the thymic epithelial cells normally
responsible for directing T-cell maturation.1 Histologically, thy-
momas frequently have an accompanying rich infiltrate of T
cells. When released into the circulation,2 these abnormally
conditioned T cells are likely responsible for the autoimmune
conditions that often accompany thymoma, such as myasthenia
gravis, blood disorders, and connective tissue diseases.3
The cause of thymoma is unknown. Because of the
rarity of this cancer, most studies of thymoma have been
based on small numbers of clinical cases recruited at single
treatment centers. In this article, the author reviews the
epidemiology of this malignancy using data collected by
population-based cancer registries to outline some possible
clues to its etiology. The author also reviews studies that
have examined the associations between thymoma and
other malignancies, because such studies can shed light on
risk factors that these malignancies share and thus the
biology of thymoma.
DESCRIPTIVE EPIDEMIOLOGY OF THYMOMA
Information on the demographic characteristics associ-
ated with thymoma incidence can yield clues to relevant
etiologic factors.4 In the United States, the National Cancer
Institute’s Surveillance, Epidemiology, and End Results
(SEER) program provides population-based data on cancer
incidence for 18 states and metropolitan regions (available at:
www.seer.cancer.gov). Together, the SEER cancer registries
currently cover approximately 26% of the U.S. general pop-
ulation. Reporting of all malignancies other than basal cell
and squamous cell skin cancers is mandated by U.S. state
laws, and ascertainment of invasive cancers by SEER is
considered essentially complete.
Thymomas have a variable presentation, manifesting ei-
ther concurrently with myasthenia gravis (one third of cases),
with local symptoms (e.g., chest pain, neck mass, and superior
vena cava syndrome; one third), or asymptomatically as a
mediastinal mass on chest radiography (approximately one third
of cases).5–7 Thymomas can be classified as “malignant” or
“benign” based on evidence for capsular invasion. Given the
variable presentation and apparent invasiveness, it is likely that
not all thymoma cases are captured by cancer registries, because
thymomas with a benign behavior or extent limited within
the thymic capsule might not be considered malignant by
clinicians or diagnosed as such by pathologists. If such
cases are not recorded in cancer registries, estimates of
thymoma incidence based on registry data would be arti-
factually low. The frequency of underascertainment of
thymoma by cancer registries is unknown.
Based on SEER data, the overall incidence of thymoma
in the United States is 0.13 per 100,000 person-years (Table
1). Although this estimate may be too low for the reasons
enumerated earlier in the text, it is nonetheless apparent that
thymoma is a rare cancer. For example, a simple extrapola-
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tion to the U.S. population (300 million people) would lead to
an estimate of 390 cases per year in the entire country.
Thymoma incidence has declined over time (Figure 1A), but
this trend could potentially reflect changes in the classifica-
tion of thymoma or trends in reporting to SEER. Thymoma
incidence is similar in males and females (Table 1). Thy-
moma is exceedingly uncommon in children and young
adults, rises in incidence in middle age, and peaks in the
seventh decade of life (Figure 1B). This pattern mirrors the
age-related rise in incidence for many other cancers and
presumably reflects the accumulation of genetic damage with
age.8 Nonetheless, the increase in thymoma incidence with
age is in striking contrast to the progressive involution of the
thymus with age,9 which presumably would reduce the like-
lihood of malignant transformation of thymic epithelial cells.
The decline in thymoma incidence at the oldest ages (Figure
1B) is also unexplained.
Of interest, thymoma incidence in the United States
is higher in blacks and especially Asians/Pacific Islanders
than among whites or Hispanics (Table 1). As shown in
Table 1, an elevated risk seems to be present for all
major groups of Asians/Pacific Islanders. Furthermore,
thymoma arises among blacks at a much younger age than
among whites (median age at diagnosis 48 versus 58 years,
SEER data).
Consideration of available epidemiologic data for re-
lated medical conditions may also be informative. Similar to
thymoma, myasthenia gravis is extremely rare (incidence
0.4–1.1 per 100,000 person-years),10–12 and little is known
about its epidemiology. In the United States, myasthenia
gravis may be more common in blacks than whites,12 mirror-
ing the pattern for thymoma. Also of interest, Asians have a
relatively high risk for developing cancers of the nasopharynx
and salivary gland, which (similar to thymus) derive from the
embryonic foregut.13 The reasons for this clustering of cancer
risk among Asians are unclear.
SECONDARY MALIGNANCIES ASSOCIATED
WITH THYMOMA
Careful evaluation of risk for additional cancers in
individuals with thymoma can also be informative with re-
spect to the etiology of thymoma. For example, an increased
risk of specific cancers in patients with thymoma could
indicate that those cancers share genetic or environmental
risk factors with thymoma. Additionally, an elevated risk for
specific cancers after thymoma may suggest that the immune
dysregulation caused by thymoma predisposes to those can-
cers. Finally, therapy for thymoma might increase the risk for
certain cancers, for example, related to surgery (thymectomy
leading to immunosuppression) or radiotherapy (leading to
cancers in the radiation field).
Three studies based at single treatment centers have
suggested that patients with thymoma have a broadly in-
creased risk for cancer, perhaps related to genetic predispo-
sition or immune disturbance.14–16 The secondary malignan-
cies that were described in these patient series included both
common cancers (e.g., cancers of the lung, thyroid, and
prostate and lymphomas) and rare malignancies (e.g., brain
tumors, sarcomas, and leukemias). Overall cancer risk was
estimated to be 3 to 4 times higher in patients with thymoma
than in controls.15,16 Nonetheless, a limitation of these studies
is that they were small (100–200 patients with thymoma in
each study), which precluded a precise estimate of overall
cancer risk and made them uninformative for specific cancer
types. Thus, it is not possible from these studies to determine
whether cancer risk is elevated for a wide spectrum of cancers
or whether any increased risk is restricted to a subset of
malignancies. Furthermore, patients were all treated at a
single referral center and may not be representative of other
thymoma cases. Finally, control groups that served as a basis
for comparison with patients with thymoma (i.e., patients
with parathyroid adenomas, nasopharyngeal carcinoma, or
thymectomy) were also not representative of the general
population.15,16
An alternative approach is to use cancer registry data to
compare cancer incidence in patients with thymoma to the
general population. Advantages include the availability of a
large and representative sample of thymoma cases from the
registry, systematic ascertainment of secondary malignancies
through reports to the cancer registry, and availability of
cancer rates from the general population to serve as an
appropriate comparison. The ratio of cancer incidence ob-
served in thymoma cases to cancer incidence expected based
on general population rates (standardized according to sex,
age, race, and calendar year) yields a standardized incidence
ratio (SIR) that approximates the relative risk for cancer
associated with thymoma.
TABLE 1. Thymoma Incidence in the United States (SEER
Data)
Categorya
Age-Standardized Incidence,
per 100,000 Person-Yearsb
SEER9 (1973–2006)
Overall 0.13
By sex
Males 0.14
Females 0.12
SEER13 (1992–2006)
By race/ethnicity
Non-Hispanic white 0.10
Non-Hispanic black 0.18
Hispanic 0.08
Asian/Pacific Islander 0.25
SEER18 (1998–2002)
By Asian/Pacific Islander subgroup
Chinese 0.17
Japanese 0.30
Filipino 0.18
Korean 0.17
Vietnamese 0.26
a Data are from the National Cancer Institute’s Surveillance, Epidemiology, and
End Results (SEER) program (available at: www.seer.cancer.gov). SEER9, SEER11,
and SEER18 refer to the number of cancer registries providing data for the indicated
calendar years. Data on Hispanic ethnicity and Asian/Pacific Islander subgroup were
available only beginning in 1992 and 1998, respectively.
b Rates are age-standardized to the 2000 U.S. population.
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In a 2003 study,4 Engels and Pfeiffer used SEER data
to evaluate cancer incidence in 733 U.S. patients with thy-
moma relative to the general population. The study was larger
than the three previously mentioned studies combined and
included cases drawn from a large geographic region of the
United States. Results from the study are shown in Table 2.
Secondary malignancies arose in 66 (9%) patients with thy-
moma, corresponding to an overall SIR of only 1.5, which
was a more modest elevation than seen in the hospital-based
series.15,16 Specific malignancies for which patients with
thymoma had an elevated risk included cancers of the diges-
tive system as a group (SIR, 1.8 based on 18 cases), non-
Hodgkin’s lymphoma (NHL, SIR, 4.7 based on seven cases),
and soft tissue sarcomas (SIR, 11.1 based on two cases). The
study, thus, suggests a more limited spectrum of cancers
associated with thymoma than reported in the three prior
studies.14–16
The most important association in Table 2 was for
NHL.4 Diagnostic confusion of thymic NHLs with thymoma
could potentially explain this association. Nevertheless,
among NHLs where immunophenotyping was performed, all
were of B-cell origin. Also arguing against an artifactual
explanation, NHL risk was elevated for a prolonged period
after thymoma diagnosis, with an SIR of 7.1 in the 5- to
9-year period after thymoma diagnosis. Instead, it is plausible
that abnormally functioning T cells, arising in association
with thymoma, either induce or fail to control B-cell prolif-
eration, which could then lead to NHL. Similarly, much
FIGURE 1. Thymoma incidence in
the United States, according to cal-
endar year and age at diagnosis.
Panel A shows incidence as a func-
tion of calendar year of diagnosis.
Incidence is per 100,000 person-
years and is standardized to the
2000 U.S. general population.
Panel B shows incidence as a func-
tion of age of diagnosis. Crude in-
cidence is per 100,000 person-
years. Data are from the SEER9
cancer registries (1973–2006, avail-
able at: www.seer.cancer.gov).
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higher NHL risk is present with more severe T-cell dysfunc-
tion, as seen in acquired immunodeficiency syndrome (AIDS)
or after organ transplantation,17 and in patients with autoim-
mune conditions.18,19
In the study by Engels and Pfeiffer,4 the modest in-
crease of digestive tract cancers among patients with thy-
moma was difficult to explain, because it was not due to a
clear excess at a particular site (Table 2). The increased risk
of soft tissue sarcoma was attributable to only two cases. One
of these cases was a liposarcoma, and the other was a
malignant fibrous histiocytoma in a Japanese person. The
occurrence of malignant fibrous histiocytoma is notable be-
cause a prior study described three cases of this sarcoma
among 102 Japanese patients with thymoma.20 The associa-
tion between thymoma and sarcomas might be due to shared
genetic or environmental risk factors.
As noted earlier, studies that use cancer registry data
are limited by inclusion of only malignant neoplasms. Could
this limitation have biased the results of the second cancer
study by Engels and Pfeiffer? As argued by Welsh,21 under-
ascertainment of second cancers could occur if patients with
malignant thymoma did not survive long enough to develop
a second cancer. Nevertheless, in the study by Souadjian et
al.,15 there was an approximately threefold relative risk for
second cancers in the first 5 to 10 years after thymoma. In the
study by Engels and Pfeiffer,4 the mean duration of follow-up
after thymoma diagnosis was 5.3 years; therefore, the dura-
tion of follow-up was likely long enough to detect a strongly
increased overall cancer risk. Furthermore, the duration of
follow-up should not matter if the elevated risk in patients
with thymoma is due to a shared genetic or environmental
etiology with the other cancer, because presumably that
etiologic factor has been present for years before thymoma
diagnosis. Finally, there is no clearly established biologic
reason why malignant thymomas would be intrinsically less
likely to be associated with other cancers than benign thy-
momas.
A related complementary approach uses cancer reg-
istry data to examine thymoma risk following other first
cancers. One prior report based on SEER data briefly
mentioned that there was only a modestly elevated risk of
thymoma following other cancer diagnoses (SIR, 1.33) and
that thymoma risk was not especially increased following
any particular cancer.22
Similarly, Table 3 presents risks for thymus malignan-
cies after specific selected neoplasms, using updated SEER
data. As suggested by Travis et al.,22 there is little evidence
for an increased risk of thymoma following other cancers.
Although wide confidence limits for the SIRs preclude strong
conclusions, the null findings argue against strong genetic or
environmental risk factors for thymoma that are common
with other malignancies. The absence of an increased risk of
thymoma after NHL (in distinction to the increased NHL risk
after thymoma seen in Table 2) adds support to the hypothesis
that the elevated risk of NHL arises due to the thymoma
itself, i.e., from immune dysregulation. The association with
digestive system cancers seen in Table 2 was not confirmed,
TABLE 2. Subsequent Malignancies Among U.S. Patients
with Thymoma (N  733)
Sitea
Cancers,
n (%)b
Standardized Incidence
Ratio (95% CI)
Oral cavity/pharynx 1 (0.1) 0.8 (0.0–4.5)
Digestive system 18 (2.5) 1.8 (1.1–2.9)
Esophagus 2 (0.3) 3.8 (0.5–13.6)
Stomach 3 (0.4) 2.8 (0.6–8.2)
Colon/rectum 10 (1.4) 1.7 (0.8–3.1)
Liver/biliary tract 3 (0.4) 3.8 (0.8–11.2)
Respiratory system 12 (1.6) 1.5 (0.8–2.7)
Larynx 2 (0.3) 3.8 (0.5–13.9)
Lung/bronchus 10 (1.4) 1.4 (0.7–2.6)
Female breast 6 (0.8) 1.2 (0.4–2.5)
Female reproductive system 1 (0.1) 0.4 (0.0–2.4)
Uterus 1 (0.1) 0.9 (0.0–5.0)
Ovary — 0 (0.0–4.5)c
Male reproductive system 10 (1.4) 1.3 (0.6–2.4)
Prostate 10 (1.4) 1.3 (0.6–2.4)
Urinary system 3 (0.4) 0.9 (0.2–2.8)
Kidney 1 (0.1) 1.1 (0.0–6.3)
Bladder 2 (0.3) 1.0 (0.1–3.5)
Nervous system 1 (0.1) 2.2 (0.1–12.1)
Thyroid — 0 (0.0–9.4)c
Bones/joints — 0 (0.0–74.9)c
Soft tissue/heart 2 (0.3) 11.1 (1.3–40.1)
Non-Hodgkin’s lymphoma 7 (1.0) 4.7 (1.9–9.6)
Hodgkin’s lymphoma — 0 (0.0–25.0)c
Leukemia 3 (0.4) 2.9 (0.6–8.4)
Multiple myeloma 1 (0.1) 1.8 (0.0–9.8)
Melanoma 1 (0.1) 1.1 (0.0–5.9)
All sites 66 (9.0) 1.5 (1.2–1.9)
Reproduced with permission from Int J Cancer.4
a The following diagnoses with zero observed events are not shown in the table:
miscellaneous cancers of the digestive system (small intestine, anus, pancreas, and
retroperitoneum), respiratory system (nasal cavity and trachea), female genital system
(cervix, vulva, and vagina), and male genital system (testis and penis); adrenal gland;
eye and orbit; mesothelioma; Kaposi’s sarcoma; and malignancies at ill-defined sites.
b Number of cancers are expressed as a percentage of patients with thymoma. Five
patients, including one patient with two breast cancers, are each counted twice.
c One-sided confidence interval.
TABLE 3. Risk of Thymoma Following Selected Other
Malignancies in the United States
First Malignancy
Thymoma
Cases, n
Standardized Incidence
Ratio (95% CI)
Digestive system 8 1.0 (0.4–2.0)
Lung/bronchus 4 1.8 (0.5–4.7)
Female breast 14 1.3 (0.7–2.2)
Non-Hodgkin’s lymphoma 2 1.4 (0.2–5.1)
Hodgkin’s lymphoma 1 3.6 ( 0.1–20)
Soft tissue/heart 1 3.9 ( 0.1–21)
All sites 68 1.3 (1.0–1.7)
Data are from the National Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) program (available at: www.seer.cancer.gov), SEER9 1973–2006.
Thymoma risk is evaluated in people who have survived for more than 2 mo after initial
cancer diagnosis.
Journal of Thoracic Oncology • Volume 5, Number 10, Supplement 4, October 2010 Thymoma and Associated Malignancies
Copyright © 2010 by the International Association for the Study of Lung Cancer S263
and although there was a suggestive increase of thymoma
following soft tissue/heart sarcomas, only one thymoma was
observed (in a patient with a liposarcoma).
Finally, the absence of increased thymoma risk follow-
ing lung cancer, breast cancer, and Hodgkin’s lymphoma, all
of which are treated with radiation therapy to the chest,
argues against ionizing radiation as a risk factor for thymoma.
Further evidence against ionizing radiation as a predisposing
factor comes from a study of infants who received thymic
radiation to treat a benign enlarged thymus.23,24 Over several
decades of follow-up, these individuals had an elevated risk
for thyroid cancer, but no thymomas were reported.
POSSIBLE RISK FACTORS FOR THYMOMA
Although limited, most available evidence regarding
risk factors for thymoma derives from descriptive epidemio-
logic studies of thymoma and associated malignancies (re-
viewed earlier). A standard approach to unraveling the etiol-
ogy of a malignancy, which usually follows the descriptive
epidemiology, is the case-control study, which can directly
compare the frequency of potentially relevant environmental
exposures, medical conditions, and genetic traits among can-
cer cases and controls. Unfortunately, no case-control study
has been conducted of thymoma, and such a study would be
difficult to implement given the rarity of this malignancy.
Table 4 lists the major risk factors considered for most
cancers and summarizes the limited evidence for thymoma.
The data reviewed earlier regarding risk of second cancers in
association with thymoma do not suggest that tobacco or
alcohol use are risk factors (i.e., absence of increased risk for
cancers caused by these exposures, such as lung cancer and
liver cancer, among patients with thymoma), but such con-
siderations can only rule out a very strong effect of these
agents. There are no available data concerning the role of
occupation, environmental exposures, or diet and nutrition.
The absence of reports regarding family clustering of
thymoma would argue against strong genetic risk factors,
although the rarity of thymoma and its onset at older ages
would make it harder to detect such clustering. In contrast,
the elevated risk among diverse Asians and Pacific Islanders
suggests a genetic component, as does the association with
malignant fibrous histiocytoma among Japanese.
Many cancers, particularly those caused by viruses,
occur at increased frequency among immunosuppressed peo-
ple. Nevertheless, based on data from a large registry linkage
study, the HIV/AIDS Cancer Match Study,25 thymoma risk
was not elevated among 516,000 people with AIDS in the
United States (four thymoma cases, SIR 0.85) (Engels, un-
published analyses). Similarly, thymoma risk does not seem
elevated among immunosuppressed solid organ transplant
recipients, as a MEDLINE literature search (conducted by the
author in July 2009) revealed no reported cases.
Viruses are implicated in other rare cancers (e.g., hu-
man herpesvirus 8 in Kaposi sarcoma), but evidence is
limited for thymoma. Two reports described detection of
human foamy virus, a retrovirus, in patients with thymoma or
myasthenia gravis,26,27 but subsequent larger studies did not
confirm the findings.28,29 In 2002, Manca et al.30 reported
finding evidence for human T-cell lymphotropic virus type 1
infection in patients with myasthenia gravis, some of whom
had thymoma, but again these findings were not confirmed.28
Differing results across studies may reflect differences in the
patient populations (e.g., geography) but more likely point to
difficulties in laboratory methods (e.g., false-positive results
caused by contamination). Evidence is more convincing that
Epstein-Barr virus is present in a subset of thymic carcino-
mas, specifically those which display a lymphoepithelial
architecture.31–34
CONCLUSION
The available data regarding the descriptive epidemi-
ology of thymoma are limited and yield few clues to the
etiology of this malignancy. Thymoma incidence is higher in
Asians/Pacific Islanders and blacks than in whites, suggesting
that there may be genetic risk factors. This hypothesis is
supported by the association between thymoma and sarco-
mas, particularly malignant fibrous histiocytoma among Jap-
anese individuals. Given the contribution of genetic variation
in development of other cancers, it would indeed be surpris-
ing if genetic risk factors were not present for thymoma. In
TABLE 4. Potential Risk Factors for Thymoma
Cancer Risk Factor
Evidence Regarding
Relevance in Thymomaa Comment
Tobacco/alcohol  Absence of increased risk of tobacco and alcohol-related cancers
Ionizing radiation  No increased risk after radiation for benign enlarged thymus or other cancers
Occupation 0 No data
Environmental contaminants 0 No data
Diet and nutrition 0 No data
Genetic variants  No family clustering. However, increased risk among Asians/Pacific Islanders, and association
with sarcomas, are suggestive
Immunosuppression  No increased risk in HIV-infected people or transplant recipients
Infections  Unconfirmed reports of associations with viral infections. However, EBV is likely involved
in lymphoepithelial carcinoma variant
a Symbols range from three minus signs (strong evidence against relevance), to a 0 (no evidence), to three plus signs (strong evidence for relevance).
EBV, Epstein-Barr virus; HIV, human immunodeficiency virus.
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the end, large multicenter case-control studies will be re-
quired to formally evaluate environmental and genetic risk
factors for thymoma.
Research evaluating risk of second cancers among
patients with thymoma has been somewhat inconclusive and
limited by the rarity of thymoma. Studies based at single
treatment centers have suggested a broadly increased risk for
diverse malignancies, whereas another study that used data
obtained from population-based cancer registries implicated a
more limited spectrum of cancers. An elevated risk of NHL
after thymoma plausibly arises as a result of disturbed T-cell
immune function caused by thymoma or its treatment.
Looking at the future of descriptive epidemiologic
studies of thymoma, it would be of interest to evaluate
incidence patterns across several countries, to determine
whether differences exist that might reflect variation in envi-
ronmental or genetic risk factors. A key consideration is the
underascertainment of thymoma by cancer registries, which
occurs because clinicians and registrars consider some cases
without apparent capsular invasion to be benign. To the
extent that there is a consensus concerning the fundamental
similarity across thymoma variants, cancer registries should
endeavor to collect information on all cases of thymoma
regardless of apparent invasiveness. Studies that jointly eval-
uate the descriptive epidemiology of both thymoma and
myasthenia gravis might also provide valuable etiologic
information.
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